Free Trial

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics logo
$4.20 -0.05 (-1.18%)
As of 04:00 PM Eastern

Foghorn Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
7

Based on 8 Wall Street analysts who have issued ratings for Foghorn Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 1 has given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for FHTX.

Consensus Price Target

$12.13
188.69% Upside
According to the 8 analysts' twelve-month price targets for Foghorn Therapeutics, the average price target is $12.13. The highest price target for FHTX is $20.00, while the lowest price target for FHTX is $9.00. The average price target represents a forecasted upside of 188.69% from the current price of $4.20.
Get the Latest News and Ratings for FHTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Foghorn Therapeutics and its competitors.

Sign Up

FHTX Analyst Ratings Over Time

TypeCurrent Forecast
4/30/24 to 4/30/25
1 Month Ago
3/31/24 to 3/31/25
3 Months Ago
1/31/24 to 1/30/25
1 Year Ago
5/1/23 to 4/30/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$12.13$13.17$13.17$14.50
Forecasted Upside188.69% Upside260.73% Upside203.38% Upside165.57% Upside
Consensus Rating
Buy
Buy
Buy
Moderate Buy

FHTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FHTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Foghorn Therapeutics Stock vs. The Competition

TypeFoghorn TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.82
2.54
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside188.69% Upside3,330.28% Upside20.72% Upside
News Sentiment Rating
Positive News

See Recent FHTX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/30/2025JMP Securities
2 of 5 stars
Silvan Tuerkcan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.00+116.35%
4/30/2025HC Wainwright
1 of 5 stars
Andres Maldonado
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00+205.88%
4/23/2025Citigroup
2 of 5 stars
 Initiated CoverageOutperform
4/23/2025Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Tuerkcan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMkt Outperform$9.00+112.26%
1/30/2025B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kalpit Patel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00+151.26%
12/16/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$18.00 ➝ $14.00+179.44%
9/24/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$6.00 ➝ $9.00-3.43%
8/19/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Clark-Gartner
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$20.00+219.49%
8/8/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$13.00 ➝ $13.00+148.09%
6/28/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$21.00 ➝ $19.00+120.93%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:49 PM ET.


FHTX Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Foghorn Therapeutics is $12.13, with a high forecast of $20.00 and a low forecast of $9.00.

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Foghorn Therapeutics in the last year. There is currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" FHTX shares.

According to analysts, Foghorn Therapeutics's stock has a predicted upside of 188.69% based on their 12-month stock forecasts.

Foghorn Therapeutics has been rated by research analysts at B. Riley, Citigroup, Citizens Jmp, HC Wainwright, and JMP Securities in the past 90 days.

Analysts like Foghorn Therapeutics more than other "medical" companies. The consensus rating for Foghorn Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FHTX compares to other companies.


This page (NASDAQ:FHTX) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners